Attached files
| file | filename |
|---|---|
| S-1/A - S-1/A - Vitae Pharmaceuticals, Inc | a2221229zs-1a.htm |
| EX-10.12 - EX-10.12 - Vitae Pharmaceuticals, Inc | a2221275zex-10_12.htm |
| EX-10.7 - EX-10.7 - Vitae Pharmaceuticals, Inc | a2221275zex-10_7.htm |
| EX-10.11 - EX-10.11 - Vitae Pharmaceuticals, Inc | a2221275zex-10_11.htm |
| EX-10.6 - EX-10.6 - Vitae Pharmaceuticals, Inc | a2221275zex-10_6.htm |
| EX-10.9 - EX-10.9 - Vitae Pharmaceuticals, Inc | a2221275zex-10_9.htm |
| EX-10.10 - EX-10.10 - Vitae Pharmaceuticals, Inc | a2221275zex-10_10.htm |
| EX-10.8 - EX-10.8 - Vitae Pharmaceuticals, Inc | a2221275zex-10_8.htm |
Exhibit 10.13
CONFIDENTIAL TREATMENT REQUESTED
AMENDMENT AGREEMENT NO. 3 TO THE RESEARCH COLLABORATION
AND LICENSE AGREEMENT
This Amendment Agreement No. 3 (“Amendment 3”) is made to the BACE Research Collaboration and License Agreement between Vitae Pharmaceuticals, Inc. (“Vitae”), with offices at 502 West Office Center Drive, Fort Washington, PA 19034, USA (taxpayer ID number 04-03567753), and Boehringer Ingelheim International GmbH (“BI”), with offices at Binger Strasse 173, 55216 Ingelheim am Rhein, Germany (VAT ID number DE 11138149), effective as of June 4, 2009, as last amended by the Amendment No. 2 (“Amendment 2”) dated December 21, 2012 (together the “Agreement”).
WHEREAS, according to Article 3 of the Amendment 2 Vitae and BI have agreed to extend the Core Indication and according to Section 4.b to a Development milestone for Candidate Feasibility.
WHEREAS, BI is developing **** and has decided to move the Development Candidate into Phase I studies.
Therefore, the Parties agree to the following:
1. If not defined in this Amendment all words capitalized in this Amendment shall have the same meaning as defined in the Agreement.
2. The full milestone payment for Initiation of Phase I studies according to Section 9.3.1 for **** all be due upon execution of this Amendment 3 and receipt of an invoice fulfilling the criteria according to the Agreement.
3. Article 4 of Amendment 2 shall be replaced as follows:
“For the first achievement of the Development milestone of Candidate Feasibility in a Core Indication according to Section 3.b. of this Amendment, BI shall pay Vitae US $1,000,000 (one million dollars). For achievement of all other Development and regulatory milestones, the milestone payments as provided in Section 9.3 of the Agreement remain unchanged.”
4. Save as amended, all other terms and conditions of the Agreement shall remain unchanged.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.
SIGNATURES FOLLOW.]
****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTION.
IN WITNESS WHEREOF, Vitae and BI, by their duly authorized officers, have executed this Amendment as of the last date signed below.
|
VITAE PHARMACEUTICALS, INC. |
|
BOEHRINGER INGELHEIM | ||||
|
|
|
|
INTERNATIONAL GMBH | |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: |
December 6, 2013 |
|
Date: |
December 6, 2013 |
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Jeff Hatfield |
|
By: |
/s/ Klaus Wilgenbus |
|
/s/ Dorothee Schall Rudolph |
|
|
|
|
|
|
|
|
|
Name: |
Jeff Hatfield |
|
Name: |
Wilgenbus |
|
Schall Rudolph |
|
|
|
|
|
|
|
|
|
Title: |
CEO |
|
Title: |
authorized signatory |
|
Authorized Signatuory |